MERCILON TABLET

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

有効成分:

DESOGESTREL; ETHINYLESTRADIOL

から入手可能:

ORGANON SINGAPORE PTE. LTD.

ATCコード:

G03AA09

投薬量:

0.15 mg

医薬品形態:

TABLET

構図:

DESOGESTREL 0.15 mg; ETHINYLESTRADIOL 0.02 mg

投与経路:

ORAL

処方タイプ:

Prescription Only

製:

N V ORGANON

認証ステータス:

ACTIVE

承認日:

1991-06-19

情報リーフレット

SG-CCPPI-OG8276A-T-112021
MercilonⓇ
USER PACKAGE LEAFLET FOR MERCILONⓇ
Read all of this leaflet carefully before you start using this
medicine.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, please ask your doctor or
pharmacist.
•
This medicine has been prescribed for you. Do not pass it on to
others. It may harm them, even if their
symptoms are the same as yours.
•
If any of the side effects gets serious, or if you notice any side
effects not listed in this leaflet, please tell your
doctor or pharmacist.
In this leaflet:
1. What is MercilonⓇ and what is it used for?
2. Before you start to use MercilonⓇ
2.1. When should you not use MercilonⓇ?
2.2. When do you need to take special care with MercilonⓇ?
2.3. When should you contact your doctor?
2.4. More about hormonal contraceptives
3. How do you use MercilonⓇ?
3.1. When and how to take the tablets?
3.2. Starting your first pack of MercilonⓇ
3.3. If too many MercilonⓇ tablets are taken (overdose)
3.4. What to do if…
3.5. If you want to stop taking MercilonⓇ
4. Possible side effects
5. How to store MercilonⓇ?
6. Further information
6.1. What MercilonⓇ contains
6.2. What MercilonⓇ looks like and content of the pack
6.3. Product Registrant
6.4. Last revision of this package leaflet
1. WHAT IS MERCILONⓇ AND WHAT IS IT USED FOR?
Composition and type of Pill
MercilonⓇ is a combined oral contraceptive ('the combined Pill').
Each tablet contains a small amount of two
different female hormones. These are desogestrel (a progestogen) and
ethinylestradiol (an estrogen). Because of
the small amounts of hormones, MercilonⓇ is considered a low-dose
oral contraceptive. As all tablets in the pack
combine the same hormones in the same dose, it is considered a
monophasic combined oral contraceptive.
Why use MercilonⓇ?
MercilonⓇ is used to prevent pregnancy.
When taken correctly (without missing tablets), the chance of becoming
pregnant is very low.
2. BEFORE YOU START TO USE MERCILONⓇ
2.1 When s

製品の特徴

SG-CCDS-OG8276A-T-112021
1. NAME OF THE MEDICINAL PRODUCT
MercilonⓇ tablets
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 0.150 mg desogestrel and 0.020 mg
ethinylestradiol.
Excipient: lactose < 80 mg
For a full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Tablets for oral use
Tablets are round, biconvex and 6 mm in diameter. They are coded on
one side TR above 4 and on the
reverse side Organon*.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Oral Contraception.
4.2 Posology and method of administration
4.2.1 How to take MercilonⓇ
Tablets must be taken in the order directed on the package every day
at about the same time with some
liquid as needed. One tablet is to be taken daily for 21 consecutive
days. Each subsequent pack is started
after a 7-day tablet-free interval, during which time a withdrawal
bleed usually occurs. This usually starts
on day 2-3 after the last tablet and may not have finished before the
next pack is started.
4.2.2 How to start taking MercilonⓇ
No preceding hormonal contraceptive use [in the past month]
Tablet-taking has to start on day 1 of the woman’s natural cycle
(i.e., the first day of her menstrual
bleeding). Starting on days 2-5 is allowed, but during the first cycle
a barrier method is recommended in
addition for the first 7 days of tablet-taking.
Changing from a combined hormonal contraceptive (combined oral
contraceptive (COC), vaginal ring, or
transdermal patch)
The woman should start with MercilonⓇ preferably on the day after
the last active tablet (the last tablet
containing the active substances) of her previous COC, but at the
latest on the day following the usual
tablet-free or placebo tablet interval of her previous COC. In case a
vaginal ring or transdermal patch has
been used, the woman should start using MercilonⓇ preferably on the
day of removal, but at the latest
when the next application would have been due.
If the woman has been using her previous method consistently and
correctly and if it is reasonably certain
tha